<DOC>
	<DOCNO>NCT01762124</DOCNO>
	<brief_summary>The purpose early feasibility study determine new transcatheter pulmonary valve move perform implant right ventricular outflow tract .</brief_summary>
	<brief_title>Study Native Outflow Tract Transcatheter Pulmonary Valve ( TPV )</brief_title>
	<detailed_description>Medtronic , Inc. process develop novel transcatheter device option patient congenital heart disease , without right ventricle-to-pulmonary artery conduit , call Native Outflow Tract Transcatheter Pulmonary Valve . Given limitation animal model confirm device boundary condition , feasibility study propose characterize information well evaluate safety , procedural feasibility performance data use future development device .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Tetralogy Fallot</mesh_term>
	<criteria>Subject pulmonary regurgitation per one follow criterion : Severe pulmonary regurgitation measure Doppler echocardiography , Pulmonary regurgitant fraction ≥ 30 % measure cardiac magnetic resonance image Clinical indication surgical placement RVOT conduit bioprosthetic pulmonary valve per one follow criterion : Subject symptomatic secondary pulmonary insufficiency ( e.g . exercise intolerance , fluid overload ) classify Investigator , Right ventricular end diastolic volume ( RVEDV ) ≥ 150 ml/m2 Subject willing consent participate study commit completion followup requirement Anatomy unable accommodate 25 Fr delivery system Obstruction central vein Clinical biological sign infection include active endocarditis Indicated intervention stenosis branch pulmonary artery time implant Positive pregnancy test baseline ( prior CT angiography prior implant procedure ) female subject child bear potential Patients right ventricular outflow tract obstruction ( RVOTO ) lesion surgically treat right ventricletopulmonary artery conduit implant A major progressive noncardiac disease ( e.g . liver failure , renal failure , cancer ) result life expectancy le one year Planned implantation Native Outflow Tract TPV leave heart RVOT anatomy morphology unfavorable anchor Known allergy aspirin , heparin , nickel Echocardiographic evidence intracardiac mass , thrombus , vegetation Preexisting prosthetic heart valve prosthetic ring position Patient currently enrol another investigational device drug trial may influence outcome trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary valve</keyword>
	<keyword>Congenital heart disease</keyword>
	<keyword>Transcatheter pulmonary valve</keyword>
	<keyword>Percutaneous pulmonary valve</keyword>
</DOC>